Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

295.77 -3.06 (-1.02%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 10, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,432,597
Open 301.20
Bid (Size) 294.50 (1)
Ask (Size) 298.64 (1)
Prev. Close 298.83
Today's Range 295.11 - 301.80
52wk Range 176.36 - 301.80
Shares Outstanding 259,428,394
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Acadia Terminates Painkiller, Cancer Candidate After Disappointing Data
 
Via Benzinga
Peering Into Vertex Pharmaceuticals Recent Short Interest
Vertex Pharmaceuticals' (NASDAQ:VRTX) short percent of float has risen 13.71% since its last report. The company recently reported that it has 3.59 million shares... 
Via Benzinga

Performance

YTD
+32.91%
+32.91%
1 Month
+0.58%
+0.58%
3 Month
+25.88%
+25.88%
6 Month
+21.10%
+21.10%
1 Year
+50.55%
+50.55%

More News

Read More
Vertex Makes Bullish Move On Earnings, Leading 5 Stocks To Watch
Via Investor's Business Daily
Where Vertex Pharmaceuticals Stands With Analysts
Via Benzinga
Pfizer Is Reportedly In 'Advanced Talks' To Buy Global Blood Therapeutics For $5 Billion
Via Investor's Business Daily
$1000 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Vertex Pharma Easily Beats Quarterly Forecasts And Raises 2022 Outlook
Via Investor's Business Daily
Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review
Via Investor's Business Daily
Vertex Pharmaceuticals: Q2 Earnings Insights
Via Benzinga
Vertex Reports Second Quarter 2022 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
Via Benzinga
Oil Falls Amid Rise In Reserves, China Is Creating A Blockade On Taiwan
Via Talk Markets
These 4 Key Sectors Can Be Especially Profitable In A Rising Interest Rate Environment
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Daily Biotech Pulse: VistaGen's Anxiety Study Fails, Silverback To Merge With Firm Developing EpiPen Alternative, Setback For Liminal's Lead Asset
Via Benzinga
Vertex Advances VX-548 in Acute and Neuropathic Pain
From Vertex Pharmaceuticals Incorporated
Via Business Wire
7 Stocks for Beginners to Buy Now
Via InvestorPlace
Peering Into Vertex Pharmaceuticals's Recent Short Interest
Via Benzinga
Daily Biotech Pulse: Liver Disease-Focused Gene Therapy Pact, Assembly Bio Stops HBV Infection Trial, X4 Pharma Looks For Partners
Via Benzinga
CNBC's Final Trades: Foot Locker, Vertex Pharmaceuticals And This Investment Management Company
Via Benzinga
Verve Therapeutics, Vertex Join Forces For Liver Disease-Focused Gene Program
Via Benzinga
Goldman Sachs, Costco Get CNBC Fast Money Mentions, With This Stock Jumping 0.66% In Seconds
Via Benzinga
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 15 Years
Via Benzinga
Vertex to Announce Second Quarter 2022 Financial Results on August 4
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Crispr Therapeutics Stock Shows Rising Price Performance With Jump To 94 RS Rating
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.